Cardiovascular effects elicited by central administration of physostigmine via M2 muscarinic receptors in conscious cats

Ahmmed Ally, L. Britt Wilson, Antonio C L Nóbrega, Jere H. Mitchell

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The cardiovascular effects of an intracerebroventricular (i.c.v.) injection of physostigmine were studied using conscious cats. Physostigmine (5-25 μg: 5 μl) caused a dose-dependent increase in mean arterial pressure (MAP) and heart rate (HR). The highest dose (25 μg) increased MAP and HR by 32 ± 3 mmHg and 45 ± 5 beats/min, respectively (n = 5). Pre-administration of the muscarinic receptor antagonist, atropine (25 μg; i.c.v.) blocked the effects of physostigmine (25 μg; i.c.v.). Also, the pre-administration of the M2 muscarinic antagonist, methoctramine (25 μg; i.c.v.), antagonized the cardiovascular effects of physostigmine without altering the baseline variables. However, the M1 muscarinic antagonist, pirenzepine (100 μg; i.c.v.) did not alter baseline MAP or HR, and also failed to inhibit the cardiovascular responses to physostigmine. Similarly, the M3 muscarinic blocker, 4-diphenyl-acetoxy-N-methylpiperidine methiodide (50 μg; i.c.v.), neither changed baseline cardiovascular variables nor blocked the effects of physostigmine. When the same cats were anesthetized with intravenous injection of sodium pentobarbital (25-30 mg/kg), physostigmine (25 μg; i.c.v.) evoked a decrease in MAP and HR of 13 ± 6 mmHg and 15 ± 6 bpm, respectively (n = 5). These results demonstrate that the increases in MAP and HR to the i.c.v. administration of physostigmine in conscious cats arepossibly mediated through stimulation of central M2 muscarinic receptors. In addition, anesthesia reverses the effects elicited by the central administration of physostigmine to a decrease in MAP and HR.

Original languageEnglish (US)
Pages (from-to)268-276
Number of pages9
JournalBrain Research
Volume677
Issue number2
DOIs
StatePublished - Apr 24 1995

Fingerprint

Muscarinic M2 Receptors
Physostigmine
Cats
Arterial Pressure
Heart Rate
Muscarinic Antagonists
Pirenzepine
Muscarinic Receptors
Pentobarbital
Atropine
Intravenous Injections
Cholinergic Agents
Anesthesia

Keywords

  • 4-DAMP
  • Anesthesia
  • Atropine
  • Heart rate
  • Intracerebroventricular
  • Mean arterial pressure
  • Methoctramine
  • Pirenzepine

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Cardiovascular effects elicited by central administration of physostigmine via M2 muscarinic receptors in conscious cats. / Ally, Ahmmed; Britt Wilson, L.; Nóbrega, Antonio C L; Mitchell, Jere H.

In: Brain Research, Vol. 677, No. 2, 24.04.1995, p. 268-276.

Research output: Contribution to journalArticle

@article{c71cdc72388f43ae9ed2815be4987fe1,
title = "Cardiovascular effects elicited by central administration of physostigmine via M2 muscarinic receptors in conscious cats",
abstract = "The cardiovascular effects of an intracerebroventricular (i.c.v.) injection of physostigmine were studied using conscious cats. Physostigmine (5-25 μg: 5 μl) caused a dose-dependent increase in mean arterial pressure (MAP) and heart rate (HR). The highest dose (25 μg) increased MAP and HR by 32 ± 3 mmHg and 45 ± 5 beats/min, respectively (n = 5). Pre-administration of the muscarinic receptor antagonist, atropine (25 μg; i.c.v.) blocked the effects of physostigmine (25 μg; i.c.v.). Also, the pre-administration of the M2 muscarinic antagonist, methoctramine (25 μg; i.c.v.), antagonized the cardiovascular effects of physostigmine without altering the baseline variables. However, the M1 muscarinic antagonist, pirenzepine (100 μg; i.c.v.) did not alter baseline MAP or HR, and also failed to inhibit the cardiovascular responses to physostigmine. Similarly, the M3 muscarinic blocker, 4-diphenyl-acetoxy-N-methylpiperidine methiodide (50 μg; i.c.v.), neither changed baseline cardiovascular variables nor blocked the effects of physostigmine. When the same cats were anesthetized with intravenous injection of sodium pentobarbital (25-30 mg/kg), physostigmine (25 μg; i.c.v.) evoked a decrease in MAP and HR of 13 ± 6 mmHg and 15 ± 6 bpm, respectively (n = 5). These results demonstrate that the increases in MAP and HR to the i.c.v. administration of physostigmine in conscious cats arepossibly mediated through stimulation of central M2 muscarinic receptors. In addition, anesthesia reverses the effects elicited by the central administration of physostigmine to a decrease in MAP and HR.",
keywords = "4-DAMP, Anesthesia, Atropine, Heart rate, Intracerebroventricular, Mean arterial pressure, Methoctramine, Pirenzepine",
author = "Ahmmed Ally and {Britt Wilson}, L. and N{\'o}brega, {Antonio C L} and Mitchell, {Jere H.}",
year = "1995",
month = "4",
day = "24",
doi = "10.1016/0006-8993(95)00171-L",
language = "English (US)",
volume = "677",
pages = "268--276",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Cardiovascular effects elicited by central administration of physostigmine via M2 muscarinic receptors in conscious cats

AU - Ally, Ahmmed

AU - Britt Wilson, L.

AU - Nóbrega, Antonio C L

AU - Mitchell, Jere H.

PY - 1995/4/24

Y1 - 1995/4/24

N2 - The cardiovascular effects of an intracerebroventricular (i.c.v.) injection of physostigmine were studied using conscious cats. Physostigmine (5-25 μg: 5 μl) caused a dose-dependent increase in mean arterial pressure (MAP) and heart rate (HR). The highest dose (25 μg) increased MAP and HR by 32 ± 3 mmHg and 45 ± 5 beats/min, respectively (n = 5). Pre-administration of the muscarinic receptor antagonist, atropine (25 μg; i.c.v.) blocked the effects of physostigmine (25 μg; i.c.v.). Also, the pre-administration of the M2 muscarinic antagonist, methoctramine (25 μg; i.c.v.), antagonized the cardiovascular effects of physostigmine without altering the baseline variables. However, the M1 muscarinic antagonist, pirenzepine (100 μg; i.c.v.) did not alter baseline MAP or HR, and also failed to inhibit the cardiovascular responses to physostigmine. Similarly, the M3 muscarinic blocker, 4-diphenyl-acetoxy-N-methylpiperidine methiodide (50 μg; i.c.v.), neither changed baseline cardiovascular variables nor blocked the effects of physostigmine. When the same cats were anesthetized with intravenous injection of sodium pentobarbital (25-30 mg/kg), physostigmine (25 μg; i.c.v.) evoked a decrease in MAP and HR of 13 ± 6 mmHg and 15 ± 6 bpm, respectively (n = 5). These results demonstrate that the increases in MAP and HR to the i.c.v. administration of physostigmine in conscious cats arepossibly mediated through stimulation of central M2 muscarinic receptors. In addition, anesthesia reverses the effects elicited by the central administration of physostigmine to a decrease in MAP and HR.

AB - The cardiovascular effects of an intracerebroventricular (i.c.v.) injection of physostigmine were studied using conscious cats. Physostigmine (5-25 μg: 5 μl) caused a dose-dependent increase in mean arterial pressure (MAP) and heart rate (HR). The highest dose (25 μg) increased MAP and HR by 32 ± 3 mmHg and 45 ± 5 beats/min, respectively (n = 5). Pre-administration of the muscarinic receptor antagonist, atropine (25 μg; i.c.v.) blocked the effects of physostigmine (25 μg; i.c.v.). Also, the pre-administration of the M2 muscarinic antagonist, methoctramine (25 μg; i.c.v.), antagonized the cardiovascular effects of physostigmine without altering the baseline variables. However, the M1 muscarinic antagonist, pirenzepine (100 μg; i.c.v.) did not alter baseline MAP or HR, and also failed to inhibit the cardiovascular responses to physostigmine. Similarly, the M3 muscarinic blocker, 4-diphenyl-acetoxy-N-methylpiperidine methiodide (50 μg; i.c.v.), neither changed baseline cardiovascular variables nor blocked the effects of physostigmine. When the same cats were anesthetized with intravenous injection of sodium pentobarbital (25-30 mg/kg), physostigmine (25 μg; i.c.v.) evoked a decrease in MAP and HR of 13 ± 6 mmHg and 15 ± 6 bpm, respectively (n = 5). These results demonstrate that the increases in MAP and HR to the i.c.v. administration of physostigmine in conscious cats arepossibly mediated through stimulation of central M2 muscarinic receptors. In addition, anesthesia reverses the effects elicited by the central administration of physostigmine to a decrease in MAP and HR.

KW - 4-DAMP

KW - Anesthesia

KW - Atropine

KW - Heart rate

KW - Intracerebroventricular

KW - Mean arterial pressure

KW - Methoctramine

KW - Pirenzepine

UR - http://www.scopus.com/inward/record.url?scp=0028950958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028950958&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(95)00171-L

DO - 10.1016/0006-8993(95)00171-L

M3 - Article

C2 - 7552252

AN - SCOPUS:0028950958

VL - 677

SP - 268

EP - 276

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 2

ER -